Paediatric Dentistry Department, Univ Rennes 1, CHU de Rennes, Rennes, France.
INSERM, INRAE, Univ Rennes 1, CHU de Rennes, Nutrition Metabolisms and Cancer, Rennes, France.
Eur Arch Paediatr Dent. 2021 Oct;22(5):801-811. doi: 10.1007/s40368-021-00620-7. Epub 2021 Apr 11.
Management of a child's anxiety early in their treatment is essential in dentistry. Sedative medications are used to overcome increased anxiety from previous appointments and to promote the cooperation of children during treatment. Hydroxyzine is currently prescribed to young patients as part of the first level of conscious sedation. The main objective was to evaluate the professional practice of oral hydroxyzine, when prescribed for children presenting anxiety during dental treatment procedure performed by students and senior practitioners.
A retrospective study of dental records and questionnaires was conducted at the Dental Care Centre of the University Hospital of Rennes, France. Parameters related to the prescription of hydroxyzine in children were evaluated as potential predictors of the dental session success, with adjustments on potential confounders.
The therapeutic outcome was very encouraging with 78.3% of success during dental sessions under sedation with oral hydroxyzine. Anxiety levels before the dental procedure and the medication compliance of the child were the main predictors of success. On the other hand, lower age (< 6 years old) and longer treatments (such as pulpotomy) worsened the outcome.
Careful analysis of the literature and results of this work showed the safety of hydroxyzine within the maximum dose authorized without adverse effects, compared to other molecules described and commonly used in dentistry. No adverse effects during dental procedure were noted. This allows for minimal sedation with efficiency for the great majority of pediatric treatment. This solution should be the first step in sedation to help practicing clinicians.
在儿童治疗早期管理其焦虑非常重要。镇静药物用于克服因先前预约而增加的焦虑，并促进儿童在治疗过程中的配合。羟嗪目前被开给年轻患者，作为第一级意识镇静的一部分。主要目的是评估口腔羟嗪在学生和高级从业者为表现出牙科治疗过程中焦虑的儿童开处方时的专业实践。
在法国雷恩大学医院牙科护理中心进行了一项回顾性的牙科记录和问卷调查研究。评估了在儿童中开羟嗪的相关参数，作为牙科疗程成功的潜在预测因素，并对潜在的混杂因素进行了调整。
在接受口服羟嗪镇静的牙科疗程中，治疗效果非常令人鼓舞，成功率为 78.3%。牙科治疗前的焦虑程度和儿童的药物依从性是成功的主要预测因素。另一方面，年龄较小（<6 岁）和治疗时间较长（如活髓切断术）会使结果恶化。
仔细分析文献和这项工作的结果表明，羟嗪在最大允许剂量内是安全的，没有不良反应，与描述和常用于牙科的其他分子相比。在牙科手术过程中没有观察到不良反应。这允许在大多数儿科治疗中进行最小镇静，具有高效性。这种解决方案应该是镇静的第一步，以帮助执业临床医生。
